Casaasdas

A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

Por um escritor misterioso
Last updated 16 abril 2025
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
WO2021067465A1 - Treating spondyloarthritic and psoriatic conditions with upadacitinib - Google Patents
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Poster Abstract Presentation Abstracts - 2023 - International Journal of Rheumatic Diseases - Wiley Online Library
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study - Irene E. van der Horst-Bruinsma, Rianne E.
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Poster Abstract Presentation Abstracts - 2023 - International Journal of Rheumatic Diseases - Wiley Online Library
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Oscar IRVIN-SELLERS, Medigene AG
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Physical activity in ankylosing spondylitis: evaluation and analysis of an eHealth tool
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. - Abstract - Europe PMC
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data - Baraliakos - 2005 - Arthritis Care & Research - Wiley Online Library
Recomendado para você
você pode gostar

© 2014-2025 progresstn.com. All rights reserved.